Skip to search formSkip to main contentSkip to account menu

PRT062070

Known as: Syk-JAK Inhibitor PRT062070, Syk/JAK Inhibitor PRT062070 
An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Syk inhibitors in clinical development for hematological malignancies
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic… 
2017
2017
Kombinierte SYK-JAK-Hemmung bei NHL
S er gi i F ig ur ny i/ Fo to lia damit schlechte Prognose bei AML sein. Von 242 Patienten der HOVON/SAKK-H102-Studie hatten 20… 
2015
2015
Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity.
8531 Background: Inhibition of SYK and JAK independently has demonstrated clinical activity in patients with B cell malignancies… 
2015
2015
Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies
Background: Background: Subsets of B cell lymphomas demonstrate a reliance on B-cell receptor (BCR) and/or cytokine JAK/STAT… 
2015
2015
The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling
The emergence of B cell receptor (BCR) kinase inhibitors has proved effective for the treatment of a number of B-cell… 
Highly Cited
2014
Highly Cited
2014
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
The heterogeneity and severity of certain autoimmune diseases and B-cell malignancies warrant simultaneous targeting of multiple… 
2014
2014
Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies.
2619 Background: Syk and Jak appear to have independent but cooperative roles in promoting the survival of certain B cell… 
2014
2014
A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies
Introduction: Preclinical studies of the Syk-mediated B-cell receptor pathway and Jak-mediated cytokine pathways have… 
2013
2013
Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma
With increasing understanding of the genetic basis of diffuse large B cell lymphoma (DLBCL), more targeted therapies have been… 
2012
2012
PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.
Abstract 2764 The heterogeneity and severity of certain autoimmune diseases and B cell malignancies warrant simultaneous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)